Colestipol cholesterol lowering intervention

Description Results NMA

all cause deaths 0.76 [0.50; 1.15]

coronary deaths 0.60 [0.34; 1.06]

décès par cancer 0.98 [0.14; 6.96]

cardiac death 0.60 [0.34; 1.06]

non cardiovascular death 1.05 [0.52; 2.11]

all cause deaths 0.00 [0.00; NaN]

coronary deaths 0.00 [0.00; NaN]

cardiac death 0.00 [0.00; NaN]

non cardiovascular death NaN [NaN; NaN]

colestipol hydrochloride 32 mg/dl (n=1149)

vs.

placebo (n=1129)

double blind

Parallel groups

Sample size: 1149/1129

Primary endpoint: death

FU duration: 1.9 years

colestipol (n=23)

vs.

placebo (n=29)

Parallel groups

Sample size: 23/29

Primary endpoint:

FU duration: 1.0 years

colestipol15 g/day (n=44)

vs.

placebo (n=48)

Parallel groups

Sample size: 44/48

Primary endpoint:

FU duration: 3.0 years

colestipol 10g twice daily (n=36)

vs.

placebo (n=30)

double-blind

Parallel groups

Sample size: 36/30

Primary endpoint:

FU duration: 0.8 years

colestipol (n=21)

vs.

placebo (n=19)

Parallel groups

Sample size: 21/19

Primary endpoint:

FU duration: 3.2 years